New standard of care offers lower toxicity, shorter treatment times and improved cosmetic outcomes for women with early stage breast cancer
The American Society for Radiation Oncology (ASTRO) today announced an update to its Evidence-Based Consensus Statement for the use of Accelerated Partial Breast Irradiation (APBI) brachytherapy to include younger patients and those with low-risk ductal carcinoma in situ (DCIS).
APBI brachytherapy is a targeted form of radiation that is delivered after surgical excision of the tumor (lumpectomy) to only the area of the breast where the cancer was removed. This is accomplished by introducing a radiation source through a series of narrow tubes or struts that are placed inside the tumor cavity. APBI brachytherapy offers less radiation exposure, reduced treatment time, better cosmetic outcomes and more flexibility with respect to future treatment options.
ASTRO updated its APBI Consensus Statement to reflect data from three large-scale randomized trials evaluating APBI vs. WBI. The data from these trials were sufficiently robust that the committee voted unanimously to change the guidelines, expanding the group of patients for whom APBI brachytherapy is suitable, which now includes patients ≥50 years of age (previously, patients ≥60 years of age were included).
“Evidence-based guidelines have the potential to fundamentally alter clinical practice. These important changes to ASTRO’s guidelines were based on a systematic review of 45 published clinical studies, significantly expanding the eligible patient population,” said Atif J. Khan, MD, Director of Brachytherapy Services at the Rutgers Cancer Institute of New Jersey in New Brunswick. “Several recent clinical studies, including well-designed randomized trials directly comparing APBI to WBI, demonstrate that APBI brachytherapy offers potential advantages over WBI including a shorter course of treatment and decreased radiation while maintaining similarly low rates of cancer recurrence. We anticipate that ASTRO’s recommendations will drive significant changes in how clinicians approach early stage breast cancer treatment.”
Two decades of data have established breast conservation therapy (BCT) as the standard of care in early stage breast cancer. The traditional approach for radiation therapy as part of BCT has been a full course of whole breast irradiation (WBI), which exposes the entire breast and surrounding critical structures to radiation and requires daily treatments for four to six-and-a-half weeks.
“APBI brachytherapy is an attractive treatment option for many women with early stage breast cancer. It offers several advantages over WBI, while maintaining similar clinical outcomes, including the possibility of less radiation exposure to critical organs such as the heart, and improved cosmetic outcomes,” said Julie A. Margenthaler, MD, FACS, professor, division of general surgery at Washington University School of Medicine, chair of American Society of Breast Surgeons communications committee. “With the wide body of evidence supporting the safety and efficacy of APBI for women with early stage breast cancer and the guidelines update from ASTRO, we should soon see more widespread adoption of this clinically proven and convenient approach that targets only the tissue at risk and is kinder to patients. Indeed, treating these women with WBI may represent overtreatment.”
Elekta and Cianna Medical support ASTRO’s APBI guidelines update and are committed to improving cancer care through developing innovative medical technologies and educating women about their options. The companies encourage women to learn more about their treatment options and talk to their doctors about selecting the best individualized care plan. Additional information about APBI is also available on the ASTRO website and at bc5project.com.
“After being diagnosed with an invasive ductal carcinoma in my left breast, I underwent six weeks of radiation therapy with many unpleasant side effects,” said Rochelle Colon, a breast cancer survivor. “I remained cancer free for 15 years and then it came back on my opposite breast. Fortunately, this time my cancer was treated with APBI brachytherapy in only five short days and I experienced none of the pain or discomfort that I had previously with a longer course of radiation.”
# # #
For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, Email: firstname.lastname@example.org
Time zone: CET: Central European Time
Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, Email: email@example.com
Time zone: EST: Eastern Standard Time
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,600 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com Twitter: @Elekta.